Records containing: Melanoma (Skin Cancer)
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-27Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
-
CLINICAL_TRIALS study record update · 2026-04-22A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
-
CLINICAL_TRIALS study record update · 2026-04-20A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2026-04-16Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
-
CLINICAL_TRIALS study record update · 2026-04-15The Value of Circulating Tumour DNA in Risk Stratification in Melanoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-15Multicenter Phase 3 Randomized Controlled Trial of NO Re-excision MelanomA - NORMA 2
-
CLINICAL_TRIALS study record update · 2026-03-30A Single-Arm, Single-Center, Phase II Exploratory Study of Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma（TRIUMPH-AM）
-
CLINICAL_TRIALS study record update · 2026-03-13A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact
-
CLINICAL_TRIALS study record update · 2026-03-12A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies
-
CLINICAL_TRIALS study record update · 2026-03-09A Phase 2 Clinical Trial on Neoadjuvant Pembrolizumab in Patients Diagnosed With High-risk Melanoma Without Clinical Evidence of Metastatic Dissemination.
-
CLINICAL_TRIALS study record update · 2026-03-05PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor
-
CLINICAL_TRIALS study record update · 2026-03-03Digital Remote Patient Monitoring and Triage During Cancer Immunotherapy
-
CLINICAL_TRIALS study record update · 2026-02-25Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors
-
CLINICAL_TRIALS study record update · 2026-02-24A Multi-Reader Multi-Case Study for Evaluating the Impact of Legit.Health Plus Device on the Healthcare Practitioners' Assessment of Skin Lesions
-
CLINICAL_TRIALS study record update · 2026-02-24A Project to Enhance Dermatology E-consultations in Primary Care Centers Using Artificial Intelligence Tools.
-
CLINICAL_TRIALS study record update · 2026-02-24A Multi-Reader Multi-Case (MRMC) Study Assessing the Impact of Legit.Health Plus on the Diagnostic Accuracy and Referral Decision-Making of Primary Care Physicians for Skin Lesions.
-
CLINICAL_TRIALS study record update · 2026-02-18An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-02-18A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)
-
CLINICAL_TRIALS study record update · 2026-01-29Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
-
CLINICAL_TRIALS study record update · 2026-01-29A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-28IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-21Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma, a Phase II Double-blind Placebo-controlled Randomized Trial
-
CLINICAL_TRIALS study record update · 2026-01-15A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
-
CLINICAL_TRIALS study record update · 2026-01-08Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
-
CLINICAL_TRIALS study record update · 2026-01-06A Coordinated Approach to Peri-operative Rehabilitation to Enhance Outcomes in Melanoma: the CARE-Melanoma Pilot Randomized Controlled Trial